Search Within

Ciara Marie Kelly

Formats
  1. Meeting Abstract (44)
  2. Journal Article (37)
  3. Guidelines (4)
  4. Review (4)
  5. Book Section (1)
  6. Correspondence (1)
  7. Miscellaneous (1)
Groups
  1. Department of Medicine (92)
  2. Sarcoma Service (92)
  3. Solid Tumor Oncology Division (92)
  4. GSK Faculty (54)
  5. Hematologic Malignancies, Division of (54)
  6. Tow Center for Developmental Oncology (TCDO) (54)

More Groups

People
  1. William Tap (55)
  2. Sandra D'Angelo (51)
  3. Mark Dickson (48)
  4. Mrinal Gounder (48)
  5. Mary Keohan (46)
  6. Ping Chi (46)

More People

Years
  1. 2025 (5)
  2. 2024 (13)
  3. 2023 (10)
  4. 2022 (22)
  5. 2021 (7)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Clinical Cancer Research (10)
  3. Annals of Oncology (6)
  4. Journal for ImmunoTherapy of Cancer (6)
  5. Journal of the National Comprehensive Cancer Network (3)
  6. Nature Communications (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (33)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (9)
  4. Biomed Central Ltd (7)
  5. Elsevier Inc. (4)
  6. Nature Publishing Group (4)

More Publishers

Results (92)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with lymph node metastases; NCT03271372
    Meeting Abstract

    Chen, W.; Bhatia, S.; Brohl, A. S.; Chandra, S.; Dakhil, S.; Fecher, L. A.; Gao, L.; Gooley, T. A.; Hanna, G. J.; Hibbert, R.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53(WT) Merkel cell carcinoma (MCC)
    Meeting Abstract

    Wong, M. K.; Burgess, M.; Chandra, S.; Schadendorf, D.; Silk, A.; Olszanski, A. J.; Grob, J. J.; Jang, S.; Grewal, J. S.; Lewis, K. D.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • Management of pelvic sarcoma
    Review

    Lee, J. S.; Kelly, C. M.; Bartlett, E. K.
    European Journal of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC)
    Meeting Abstract

    Wong, M. K. K.; Burgess, M. A.; Chandra, S.; Schadendorf, D.; Silk, A. W.; Olszanski, A. J.; Grob, J. J.; Jang, S.; Grewal, J. S.; Lewis, K. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma
    Meeting Abstract

    Slotkin, E. K.; Mauguen, A.; Ortiz, M. V.; Dela Cruz, F. S.; O'Donohue, T.; Kinnaman, M. D.; Meyers, P. A.; Wexler, L. H.; Rodriguez, S.; Avutu, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition
    Meeting Abstract

    Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS)
    Meeting Abstract

    Chawla, S. P.; Kelly, C. M.; Gordon, E. M.; Quon, D. V.; Moradkhani, A.; Chua-Alcala, V. S.; Thompson, T. M.; Scheuber, A.; Bruns, I.; Allgood, V. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: Gastrointestinal stromal tumors, version 2.2022: Featured updates to the NCCN Guidelines
    Guidelines

    von Mehren, M.; Kane, J. M. 3rd; Riedel, R. F.; Sicklick, J. K.; Pollack, S. M.; Agulnik, M.; Bui, M. M.; Carr-Ascher, J.; Choy, E.; Connelly, M.; more...
    Journal of the National Comprehensive Cancer Network (2022)

    Fulltext@MSK | Save